the challenge of a universal vaccine for the Lyon-based start-up Osivax

upland-software-buys-bluevenn-for-52mn-to-boost-customer-engagement

Osivax targets a viral protein that does not mutate much. This is Osivaxs approach to developing vaccines against influenza and coronavirus. Explanations.

By Dominique MENVIELLE - 06:00 - Reading time: